Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)-Reference-Cited by-同舟云学术

Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)

Published:2020-08-10 Issue:2 Volume:24 Page:428-434
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Kurokawa Yukinori,Matsuyama Jin,Nishikawa Kazuhiro,Takeno Atsushi,Kimura Yutaka,Fujitani Kazumasa,Kawabata Ryohei,Makari Yoichi,Terazawa Tetsuji,Kawakami Hisato,Sakai Daisuke,Shimokawa Toshio,Satoh Taroh

Funder

Osaka Clinical Study Supporting Organization

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10120-020-01112-1.pdf

Reference22 articles.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Hashimoto T, Kurokawa Y, Mori M, Doki Y. Update on the treatment of gastric cancer. JMA J. 2018;1:40–9.

3. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.

4. Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3:460–8.

5. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials;Frontiers in Pharmacology;2024-01-08

2. Efficacy and safety of conversion therapy with Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in unresectable advanced gastric cancer;2023-12-13

3. Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer;Future Oncology;2023-10

4. Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer;Annals of Gastroenterological Surgery;2023-06-29

5. Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study;BMC Gastroenterology;2022-06-14